D’Incal, Claudio Peter http://orcid.org/0000-0003-1888-9066
Van Rossem, Kirsten Esther http://orcid.org/0000-0002-0463-7557
De Man, Kevin
Konings, Anthony
Van Dijck, Anke
Rizzuti, Ludovico
Vitriolo, Alessandro
Testa, Giuseppe
Gozes, Illana
Vanden Berghe, Wim http://orcid.org/0000-0003-0161-7355
Kooy, R. Frank http://orcid.org/0000-0003-2024-0485
Funding for this research was provided by:
European Research Area Networks Network of European Funding ERA-NET AUTISYN
ADNPinMED
E-Rare IMPACT
International Nucleome Consortium - OEC IPPON and COST (CA18127, CA18127)
Research Fund of the University of Antwerp OEC-Methusalem grant ‘GENOMED’ (FFB190208, FFB190208)
Article History
Received: 22 December 2022
Accepted: 16 February 2023
First Online: 21 March 2023
Change Date: 1 January 2024
Change Type: Update
Change Details: The funding section has been corrected.
Declarations
:
: Not applicable.
: The authors declare no conflict of interest. Professor Illana Gozes is a Co-Founder, Chief Scientific Officer and a Director at ATED Therapeutics, clinically developing davunetide.